Market Highlights
According to MRFR analysis, the global laboratory equipment market is expected to register a CAGR of ~7.30% during the forecast period of 2019 to 2025 and is expected to reach USD 58,960 Million by 2025. Laboratory equipment are the tools used by lab technicians or scientists to work in a laboratory. These instruments and devices aid in various tasks such as preparation of cell culture mediums for research, analysis of the biological samples of patients, studying tissues for diagnosis of various diseases, and others. The growth of the global laboratory equipment market is driven by various factors such as increasing demand for lab automation, the shift from lab-based diagnosis to the point of care diagnosis, increasing biomedical research, and rising innovations by major players. However, the lack of laboratory setups in developing countries is projected to hamper the growth of the global laboratory equipment market. The global laboratory equipment market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in October 2018, Eppendorf AG presents first internally developed the CO2 incubator. Regional Analysis The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the rising per capita healthcare expenditure. The laboratory equipment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European laboratory equipment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The laboratory equipment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing clinical laboratories and increasing pool of patient population, the market in Asia-Pacific is expected to be the fastest-growing. The laboratory equipment market in the Middle East & Africa has been divided into the Middle East and Africa. Segmentation The global laboratory equipment market has been segmented based on product type, application, and end user. The market, based on product type, has been divided into incubators, centrifuges, spectrometers, scopes, sonicators, autoclaves, and others. The incubators segment is likely to be the largest during the review period due to the growing use of this device in various areas of testing. The spectrometers segment is predicted to be the fastest-growing due to the increasing product launches in the market. For instance, in April 2018, Bruker launched INVENIO Fourier Transform Infrared (FT-IR) research spectrometer. The global laboratory equipment market has been segmented, on the basis of application, into biochemistry, endocrinology, microbiology, hematology, genetic testing, and others. The biochemistry segment is expected to hold the majority share of the market owing to the wide number of biochemical tests carried out in the laboratories. The endocrinology segment is expected to be the fastest-growing due to the rising patient pool, coupled with the increasing number of tests. The end users of the market are hospitals and clinics, diagnostic centers, and others. The hospitals and clinics segment is expected to hold the largest share of the market due to the increasing number of hospitals and clinics using laboratory equipment. The diagnostic centers segment is expected to be the fastest-growing owing to the increased preference of medical professionals for carrying out diagnostic tests. Access Report Details @ https://www.marketresearchfuture.com/reports/laboratory-equipment-market-8365 Key Players Some of the key players in the global laboratory equipment market are Agilent Technologies, Inc. (US), BD (US), Beckman Coulter, Inc. (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Eppendorf AG (Germany), F. Hoffmann LA-Roche AG (Switzerland), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific Inc. (US), and Waters (US), among others.
0 Comments
Market Highlights
The blood glucose monitoring market is one of the rapidly growing markets across the world owing to huge growth in urbanization leading to the increased incidence of obesity, unhealthy diet, and physical inactiveness, which has increased the diabetic population around the globe. Regular monitoring of glucose level is important to avoid further complications. Furthermore, invention of new technology, increasing awareness, investment in research and development have boosted the blood glucose monitoring market globally. However, high cost associated with monitoring and diagnosis of disease may restrain the market growth. The global blood glucose monitoring market is expected to grow at a CAGR of 7.1% during forecasted period 2017-2023. Regional Analysis Geographically, global blood glucose monitoring market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. The Americas commands the largest blood glucose monitoring market due to the presence of a well-developed healthcare sector and large patient population. Americas dominate the global blood glucose monitoring market owing to high healthcare spending, increasing population, increased research & development activities and the concentration of major companies have fuelled the growth of the market in this region. Europe holds the second position in the global blood glucose monitoring market owing to the government support for research & development and availability of funds for research. According to WHO, Globally, around 3.4 million people died annually owing to high blood glucose and almost 80% of these deaths occur in lower and middle income countries, and this statistics is coupled with the fact that almost 50% were people aged under 70 years. Asia Pacific is the fastest growing blood glucose monitoring market owing to the presence of rapidly developing healthcare technology, huge patient population, high healthcare expenditure, and increase in prevalence of nerve injuries or disorder related to nerve. Moreover, increasing demand for new treatment methods in countries like India and China are likely to emerge as the fastest growing market across the globe. On the other hand, in the Middle East and Africa has the lowest market for blood glucose monitoring due to lack of technical knowledge and poor medical facilities. Segmentation Global blood glucose monitoring devices market is segmented on the basis of product type, application, and end user. On the basis of the product type, it is segmented into invasive glucose monitoring devices, continuous glucose monitoring devices (CGM), flash glucose monitoring devices, and others. On the basis of the application, it is segmented into type 1 diabetes, type 2 diabetes, and others. On the basis of the end user, it is segmented into diagnostic centers, hospitals, clinics, research centers, and home care diagnostics. Key Players Some of key the players in the market are Abbott Laboratories (U.S.), Arkay, Inc. (U.S.), Bayer Healthcare AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Goldsite Diagnostics Inc., GlySure Ltd (U.K), Sphere Medical Holding plc. (U.K), Dexcom, Inc. (U.S.), and LifeScan, Inc. (U.S.). Access Report Details @ https://www.marketresearchfuture.com/reports/blood-glucose-monitoring-market-557 Blood Testing Market provides more of a high-level overview and in-depth details on more specific aspects of health functions alongside indicating current and potential health risks. Integration of several powerful technologies such as Artificial Intelligence (AI) has made the blood testing more effective. An AI-powered blood test consisting of one clinical variable and six biomarkers predicted with high accuracy the presence of peripheral artery disease and the need for revascularization in patients with and without diabetes.
Growing incidents of chronic diseases and conditions such as cancer, diabetes, heart disease along with the organ failure cases drive the demand for blood testing in multiplications. Needless to say, that the blood testing market is ever increasing. Also, great technological strides being made in electronic monitoring devices and substantial investments transpired into R&D activities are in turn, paying off well, expanding the market size. Recognizing the exponential growth, the market perceives currently and gauging the potential the market holds to grow in the years to come; Market Research Future (MRFR), in its recently published market forecast asserts that the global blood testing market will grow exponentially by 2023, registering approximately 5.5% during the review period (2017 – 2023). Additional factors supporting the market growth include the ever-increasing population that is getting inclined towards the sedentary lifestyle and urbanization. Improving economic conditions are rapidly availing access to the excellent health care, increasing the healthcare expenditures and eventually the market growth. Conversely, lack of awareness towards the availability and advantages of blood testing is obstructing the market growth. Also, the unmet clinical needs coupled with the unavailability of external funding; especially in the developing regions are obstructing the market growth. Nevertheless, increasing demand for personal & hand-held diagnostic devices & augmenting demand for the blood testing in the diagnostics that can give fastest & accurate results is fostering the market growth. Global Blood Testing Market – Segments The MRFR analysis is segmented into five key dynamics for the convenience of understanding; By Test Types : Complete Blood Count, Blood Chemistry Tests, and Enzyme Tests among others. By Diseases : Anemia, Infection, and Leukemia among others. By Methods : Manual, and Automated among others. By End-Users : Hospitals, and Diagnostic Center among others. By Regions : North America, Europe, APAC and the Rest-of-the-World (RoW). Access Report @ https://www.marketresearchfuture.com/reports/blood-testing-market-5797 Global Blood Testing Market – Regional Analysis The North America market is expected to retain its dominance over the global blood testing market with the largest market share. A well-developed healthcare sector, increasing prevalence of chronic diseases such as diabetes and cancer especially in the US & Canada along with the high per capita healthcare expenditures drive the market growth in the region. This market will create a substantial revenue pocket registering a substantial CAGR throughout the forecast period (2017-2023). Furthermore, the presence of prominent market players impacts the market growth positively. Europe & Asia Pacific region accounts for the second & third largest market respectively for the blood test. The European blood testing market is growing due to the increasing awareness of chronic infectious diseases, the initiatives undertaken by private and public organizations, and well-spread awareness towards keeping the good health. The Asia Pacific region is emerging as one of the promising markets for the blood testing. This attributes to the increasing healthcare expenditures and favorable government policies of developing economies like India and China. Factors substantiating the market growth in the APAC region include the substantial funds transpired into R&D activities, huge patient population, well-developed healthcare infrastructure, and government support. Simultaneously, economies having high healthcare expenditures such as India, China, and Japan propel the market growth in the region. Global Blood Testing Market – Competitive Analysis The market for blood testing appears fragmented and fiercely competitive due to many large and small players churning the competition in the market. Through the strategic partnership, acquisition, expansion, product & technology launch, and collaboration, these players try to gain the competitive edge. Key Players: The global blood Testing market is led by some of the fervent players including Baxter International (US), Abbott Laboratories Inc. (US), Gen-Probe, Inc. (US), Becton Dickinson & Company (US), Novartis Diagnostics (US), Biomerica, Inc. (US), Cepheid Corporation (US), Meridian Bioscience, Inc. (US), Trinity Biotech (US), Siemens Healthcare (Germany), Bio-Rad Laboratories Inc. (US), Grifols (Spain), bioMérieux (France), Nanosphere Inc. (US), Roche Diagnostics (Switzerland), Bruker Corporation (US), Alere Inc. (US), Thermo Fisher Scientific Inc. (US) Cardinal Health (US), Beckman Coulter (US), Danaher Corporation (US), and Trividia Health (US) Industry, Innovation & Related News September 07, 2018 – Scientists in Australia published their study of a novel blood test they have developed in the JCI Insight Journal. The new blood test that can potentially identify whether a person who had a heart attack in the past is at high risk of having another one. certain lipid biomarkers or fats in the blood to improve upon traditional risk factors in predicting heart disease. The researchers hope to trial it in Australia in the next two to three years. August 13, 2018 – Engineering for All (Israel), announced the development of a handheld programmable device, named as RevDx (Revolution Diagnostics) that performs automated blood analysis and diagnostics at the point of care. RevDx is meant for anyplace without reliable access to a lab, electricity or Internet connection. Overview:
The global market for dental sterilization Market is getting a nod from several quarters and is slated to reach USD 1.5 billion during the forecast period of 2018 to 2023 with a 6.9% CAGR, Market Research Future (MRFR), in a recently revealed, research report, discussed factors that can impact the global market and ensure growth. The rising prevalence of dental diseases is triggering global growth. In the US, around 90% of students show some kind of tooth-related problems. This is also getting bolstered by dietary changes that are affecting the tooth. For instance, the consumption of sugar-rich or starch-rich food is also affecting dental health owing to which the market can register better growth. It is also getting support from hospitals and other dental departments. Segmentation: The global report with a detailed understanding of the dental sterilization market, has been segmented by MRFR experts into product and end use. Data gleaned from these segments are backed by charts and graphs and factors discussed in the report are contextually analyzed to make their impact more prominent. By product, the global study on the dental sterilization market has been into consumables, instruments, and accessories. The instruments segment is leading the global market and its dominance is expected to remain unfazed during the forecast period. By end use, the global discussion on the dental sterilization market includes hospitals, dental laboratories, and others. The hospital segment has the chance to emerge as the leading one, and it will retain its position during the forecast period. This segment primarily thrives due to the infrastructural benefits and better funding. The recent technological advancements are also providing thrust for the dental laboratories. Request Free Sample: https://www.marketresearchfuture.com/sample_request/6659 Regional Analysis: North America is showing growth due to the constant rise in various technological inclusions in countries like the US and Canada. Also, these countries are quite robust in their financial structure, which is boosting the market. In Europe, countries are evolving as a dental tourism hub, which would inspire growth in the sector. In Asia Pacific, China, Japan, South Korea, and India would play a definitive role in taking the market ahead. Browse Complete Report:https://www.marketresearchfuture.com/reports/dental-sterilization-market-6659 Competitive Landscape: Dentsply Sirona, Danaher, A-Dec, Hu-Friedy, Planmeca Group, Matachana Group, Midmark, Nakanishi, Scican, W&H, Getinge, BMT Medical Technology, Tuttnaue, Crosstex, and Premier Dental are companies making a substantial impact on the global dental sterilization market with their strategic impulses. These players mostly target expansion in both client segments and portfolio. This is to strengthen its market position. Most of these strategic moves span across mergers, collaborations, innovations, better expenditure plans for various research and development projects, acquisitions, branding, marketing strategies, launching, and others. MRFR’s attempt to get the recent moves taken by these companies listed are based on the idea of understanding trends that would help in future plans. Industry News: The recent outbreak of the COVID-19 pandemic triggered unprecedented responses from countries across the world. Most of the countries have initiated lockdowns, which means the shutting off of services that are not essential. This has hampered the dental sterilization market significantly. However, the impact of the disease seems to be passing owing to which several countries are allowing a lifting up of measures in a controlled manner, which may bring back the market on its foot again. In countries like New Zealand, Iceland, Vietnam, Italy, and others, governments are providing some sort of relaxation. This is good news for the market and the revenues it had lost during the first half of 2020 is expected to be balanced by the second half. Medical document management systems are software with the capacity of storing, management, and retaining of patient documents. The changes in the healthcare sector, investments in healthcare IT, and inflow of patients are factors discussed in detail in the global medical document management systems market report by Market Research Future (MRFR). The COVID-19 pandemic and its impact on the market are explored as well.
Market Scope The global medical document management systems market size is touted to expand at a momentous growth rate owing to the increasing volume of data to be acquired in the coming years. The large influx of patients, shift to electronic health records, and the prevalence of various diseases are all main factors driving market growth. Maintenance, continuous updates, and a bid to curb rising healthcare costs can fuel the market demand in the coming years. Supportive government policies encouraging its use in the healthcare sector and a surge in interest has led to investments and fundraising in the industry. The motive to lower human errors in billing, regulatory compliance, and a sharp dip in reimbursement premiums can bode well for the market. But lack of infrastructure, skilled personnel, and funds can hamper the market growth. Request Free Sample:https://www.marketresearchfuture.com/sample_request/6578 Segmentation The global medical document management systems market has been segmented by product, application, delivery model, and end-user. By product, it is divided into services and solutions. Solutions are expected By application, it is segmented into admission registration, billing records, medical records, and others. Medical records are predicted to garner huge revenues owing to its ability to being assist in diagnosis and preventive care of patients. By delivery model, it is segmented into on-premise, cloud-based, and web-based. By end-user, it is segmented into insurance agencies, healthcare providers, hospitals clinics, and nursing homes. The healthcare providers segment is expected to be one of the biggest end-users of the global medical document management systems market owing to its need to lower data entry errors. The lowering of revenue losses due to medical billing errors can support the segment growth over the forecast period. Regional Analysis Asia Pacific (APAC), Europe, North America, and Rest-of-the-World (RW) are regions covered with respect to the prospects of the global medical document management systems market. North America is projected to be highly lucrative for the market owing to establishment of healthcare facilities, modernization of infrastructure, and shift to digital modes of record-keeping and maintenance. Healthcare insurance programs for the public such as Medicaid and Medicare, new coding standards for the medical industry, and insights gleaned from consumer data can drive the global medical document management systems market demand. Integration of analytics software to improve patient outcomes can fuel its demand. APAC is touted to showcase a phenomenal growth rate during the forecast period due to a large patient pool and need for technology to lower the burden on healthcare staff. The boom in medical tourism, switch to electronic medical records, and subsidies for public welfare are incentives likely to work in favor of the market. Browse Complete Report: https://www.marketresearchfuture.com/reports/medical-document-management-systems-market-6578 Competition Outlook Kofax Ltd., Toshiba Corporation, EPIC Systems Corporation, 3M Company, McKesson Corporation, Nextgen Healthcare Information Systems, LLC, Allscripts Healthcare Solutions Inc., Athena Health Inc., Hyland Software Inc., Siemens Medical Solutions USA Inc., GE Healthcare, and Cerner Corporation are prominent names in the global medical document management systems market. soft tissue sarcoma market Covering Competitive Scenario & Market Dynamics throughout 202711/8/2021 Market Analysis
The global soft tissue sarcoma market is projected to grow at a splendid 8.2% CAGR during the forecast period (2017-2023). This is a rare cancer that grow from soft tissues mainly deep skin tissues, nerves, fats, muscles and blood vessels. It can develop in just any part of the human body but mostly starts in the legs or arms. Apart from the legs or arms, it can be found in the internal organs, neck area, head, trunk and behind the abdominal cavity. The diagnosis method includes various physical examination including a biopsy, PET scan, ultrasound, MRI, CT scan, and X-ray imaging. These examinations together with other tests are vital for planning an appropriate treatment method for soft tissue sarcoma. Surgical removal though is the most widely used treatment, yet chemotherapy and radiation too may be suggested resting on the aggressiveness, location, type and size of the tumor. When it comes to types, there are about 50 types but of these the most common soft tissue sarcomas include undifferentiated pleomorphic sarcoma, liposarcoma, abdominal sarcoma and leiomyosarcoma. Determining its causes is difficult, however, exposure to specific chemicals such as dioxins and phenoxyacetic herbicides, previous radiotherapy exposure, specific genetic conditions and old age are predicted to boost the risk of this cancer. There are abundant factors that is propelling the growth of the soft tissue sarcoma market. These factors as per the MRFR (Market Research Future) report include increase in incidence as well as prevalence of different forms of soft tissue sarcomas, huge pipeline of drugs, strong focus on R&D for enhancing the treatment choices accessible such as biological therapies and targeted therapies, awareness amid people, rise in approvals to manufacture generics and increase in funding exclusively for research. The additional factors that is driving the market growth include rising healthcare expenditure, increase in quality patient care and increasing adoption of new drugs. On the contrary, side effects related to cancer treatment, soaring cost of treatment, strict government regulations, increasing rates of failure in clinical trials, soaring cost of radiation therapy and chemotherapy are factors that may impede the growth of the soft tissue sarcoma market. Request Free Sample: https://www.marketresearchfuture.com/sample_request/5304 Market Segmentation MRFR report offers a broad segmental analysis of the soft tissue sarcoma market on the basis of disease type, treatment, end-users and distribution channel. Based on treatment type, it is segmented into radiation therapy, anti-angiogenesis, chemotherapy, and targeted therapy. Radiation therapy is again segmented into external and internal radiation therapy. Of these, chemotherapy will have the largest share in the market during the forecast period. Based on disease type, the soft tissue sarcoma market is segmented into metastatic sarcoma, regional sarcoma and local sarcoma. Based on distribution channel, it is segmented into retail pharmacies, hospital pharmacies and others. Based on end user, the soft tissue sarcoma market is segmented into long-term care centers, oncology centers and hospitals. Of these, hospitals will dominate the market during the forecast period. Regional Analysis By region, the soft tissue sarcoma market covers growth opportunities and latest trends across Americas, Europe, Asia Pacific and Middle East and Africa. Of these, Americas account for the largest share in the market. Factors that are boosting the market growth here include presence of healthcare infrastructure that is well-established, increase in focus on healthcare, increasing awareness about soft tissue sarcoma and increasing incidences of soft tissue sarcomas. The soft tissue sarcoma market in Europe will hold the second major share during the forecast period due to boost in research and development activities for creating new drugs coupled with change in lifestyle. The market here is projected to grow tremendously. Browse Complete Report: https://www.marketresearchfuture.com/reports/soft-tissue-sarcoma-market-5304 Key Players Leading players profiled in the soft tissue sarcoma market include Celgene Corporation (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Johnson & Johnson Services, Inc. (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Bristol-Myers Squibb (U.S.), Pfizer, Inc. (U.S.), Eli Lilly and Company (U.S.), GlaxoSmithKline plc. (U.K.) and others. March 2019 – Nanobiotix SA, the French partner of PharmaEngine Inc has received the approval of the European market for PEP503 (NBTXR3) to allow in the EU the commercialization of nanoparticle radio-enhancer to treat locally advanced soft-tissue sarcoma. Global Blood Coagulation Testing Market Driven By The Increasing Prevalence Of Liver Diseases
According to the analysis of MarkeT Research Future (MRFR), the global blood coagulation testing market is expected to register a moderate CAGR of 6.5 % during the forecast period (2017-2023). The global blood coagulation testing market is driven by the adoption of advanced technologies in blood coagulation testing over the review period. Furthermore, the growing prevalence of liver disease, hemophilia, and thrombophilia are also expected to drive the market growth. However, the availability of poor reimbursement policies and expensive treatment of multiple developing countries across the world are expected to hinder the growth considerably of the global blood coagulation market over the review period. Request Free Sample: https://www.marketresearchfuture.com/sample_request/970 Segmental Analysis The global market for blood coagulation is segmented on the basis of product, application, test type, and end user. The products available in the blood coagulation market are automated testing, clinical laboratory, and semi-automated testing. On the basis of application, the blood coagulation market has been segmented into acquired bleeding disorders, hemophilia, congenital bleeding disorders, and Von Willebrand disease. By test type, the global blood coagulation market has been segmented into various testing kits and others. Additionally, testing kits are sub-segmented into activated clotting time, D dimer, and fibrinogen, (FIB prothrombin time (PT). by end user, the global blood coagulation market is segmented into academic institutions, diagnostic laboratories, and hospitals. Regional Analysis The Americas dominates the global blood coagulation testing market owing to the increasing patient with liver disease, hemophilia, and von Willebrand disease (vWF). Additionally, in North America, the early adoption of advanced technology, increasing government initiatives for research and development activities, high health care expenditure, and the presence of several significant companies contribute to the growth of the blood coagulation market in this region during the evaluation period. European region accounts for the second largest region in the global blood coagulation testing market and is likely to maintain its market share over the evaluation period. The notable growth of the region is owing to the increasing initiatives and expenditure of the government towards research and development activities. This is projected to continue to drive the European market over the forecast period. Additionally, developing countries such as Germany and France are increasing their investment in the healthcare domain to improve medical facilities. The Asia Pacific (APAC) region is the fastest growing blood coagulation testing market over the assessment period. This is attributed to the presence of rapidly developing healthcare technology, expansion of medical infrastructure, a vast patient populace, and higher healthcare expenditure. Furthermore, increasing demand for the introduction of new treatment methods in countries like India, Japan, and South Korea is likely to contribute to the substantial market share over the review period. Additionally, growing demand for quality devices in the healthcare is anticipated to increase the adoption of advanced equipment, which, consequently, is likely to surge the growth of the blood coagulation testing market in the region during the forecast period. the Middle East and Africa (MEA) region is accounted for the smallest market share over the review period. This is accredited to the increasing prevalence of blood disorders, which have become a massive problem owing to ignorance of diseases, lack of consumer awareness, limited screening, and poor access to treatment. The increase in government initiatives to improve the healthcare sector to offer necessary medical facilities, expand the infrastructure, and adopt advanced healthcare technologies, is expected to contribute substantially to the market share over the evaluation period. Additionally, the middle eastern developing countries are expected to contribute to the majority of the market share. Browse Complete Report: https://www.marketresearchfuture.com/reports/blood-coagulation-testing-market-970 Key Players The key players acknowledged in the global blood coagulation market are Accriva Diagnostics (U.S.A.), Alere Inc. (U.S.), Bio/Data Corporation (U.S.), CoaguSense, Inc. (U.S.),F. Hoffmann-La Roche Ltd. (Europe), HomoSonics LLC. (U.S.), iLine Microsystems. (Europe), Instrumentation Laboratory (U.S.), Siemens Healthcare Private Limited (Europe), Sienco, Inc. (U.S.), SenGenix Inc. (U.S.). Gene Editing Market Overview:
The global gene editing market is growing continually. The market growth attributes to the significance of gene editing processes in drug discovery diagnostics and precision medicine development. Besides, the rising prevalence of genetic diseases and cancer drives the gene editing market size. Moreover, increased RD activities, investments, numbers of biotechnology life science companies worldwide escalate the market growth to furthered height. Market Research Future (MRFR), in its gene editing market report, asserts that the market is expected to expand at 18.30% throughout the assessment period (2017–2023). Increasing cancer diagnosed cases and the proliferating biotechnology industry, alongside the advances in medical technology, act as significant driving forces. Besides, advances in genetic testing such as Next Generation Sequencing (NGS) system and its growing adoption in agriculture and animal culture boost the market growth. Gene editing has created a lot of excitement in academia and drug development, promising multi-facet benefits. Additionally, increased RD expenditures in plant animal genetic engineering, gene therapy, and microorganism genetic engineering push the growth of the market. Market Drivers and Restraints: Market Drivers:
Global Gene Editing Market - Segments The report is segmented into four dynamics; By Methods : CRISPR, TALEN, ZFN, Antisense technology, and others. By Applications : Plant Genetic Engineering, Animal Genetic Engineering, Gene Therapy, Microorganisms Genetic Engineering, and others. By End User : Biotechnology, Pharmaceutical, Contract Research Organization, and others. By Region : Americas, Europe, Asia Pacific, and the Rest-of-the-World. Request Free Sample: https://www.marketresearchfuture.com/sample_request/707 Gene Editing Market - Geographical Analysis North America dominates the global gene editing market. The largest market share attributes to massive development in drug discovery research, an increase in the number of research studies, development of the biotechnology sector. Besides, the rising prevalence of chronic diseases such as cancer and increasing expenditures for cancer care impact the regional market growth, positively. The US gene editing market, backed by the presence of many biotech companies, dominates the regional market. Moreover, enormous RD funding from public and private sectors foster the growth of the regional market. The North American gene editing market is projected to retain its dominance throughout the estimated period. Europe stands second in the global gene editing market. Increasing research development activities for cancer congenital diseases are the key driving force behind the market growth. The market is driven by substantial investments in the advancement of technology for better treatment solutions. Besides, the rising prevalence of cancer supports market growth. The European gene editing market is estimated to create a substantial reverence pocket during the projected period. The Asia Pacific gene editing market is growing briskly. Factors such as the spurting growth in the life science industry and increasing government support to boost the biotechnology sector foster the regional market growth. Moreover, the rising demand for better healthcare and the expansion of leading global genome-editing companies in the region substantiate the growth of the market. The increase in the number of laboratories and increased RD spending, act as a key tailwind for the market growth. APAC countries - India and China are showing significant progress in the gene-editing market. Besides, the development and automation of existing instrumentation systems and the rapid growth in the pharmaceutical industries foster the APAC gene editing market. Browse Complete Report: https://www.marketresearchfuture.com/reports/gene-editing-market-707 Global Gene Editing Market - Competitive Landscape The gene editing market appears to be competitive and fragmented with the presence of many players. Many well-established players alongside the new entrants form a competitive landscape. They try to gain a substantially larger competitive advantage initiating strategic initiatives such as mergers acquisitions, expansion, collaboration, and product/technology launch. Substantial investments are transpired in RD to develop new technologies that are entirely different compared to their competition. Major Players: Players leading the gene editing market include Horizon Discovery Group plc (UK), GenScript USA Inc. (US), Integrated DNA Technologies, Inc. (US), New England Biolabs, Inc. (US), Lonza Group Ltd. (Switzerland), OriGene Technologies, Inc. (US), Sigma-Aldrich Corporation (US), Sangamo Biosciences, Inc. (US), Transposagen Biopharmaceuticals, Inc. (US), and Thermo Fisher Scientific, Inc. (US), among others. Industry/ Innovation/ Related News July 23, 2020-- Tropic Biosciences (the UK), a biotechnology company, and BASF (Germany, a chemical company) announced their partnership to upgrade gene editing tech for crop development further. Under the terms of the agreement, Tropic Bio's GEiGS (Gene Editing induced Gene Silencing) technology would be studied to develop agricultural traits in BASF's strategic crop varieties that could address growers' challenges for sustainability. GEiGS utilizes established genome editing tools to make precise changes to a few nucleotides within a host organism's noncoding genome. These changes redirect RNA interference activity of noncoding genes towards target genes, including those belonging to pathogens and pests. Tropic Bio will generate crop candidates using the GEiGS platform to enter the BASF discovery pipeline to develop disease and pest control traits. Market Highlights
According to MRFR analysis, the global viral vector and plasmid DNA manufacturing market is expected to register a CAGR of ~16.9% from 2021 to 2027 and hold a value of ~USD 4,870 million in2027. The global viral vector and plasmid DNA manufacturing market is driven by the rising demand for viral vector-based vaccines for infectious diseases and a shift in the treatment paradigm of several life-threatening diseases through advanced the rapies and technological advancements in viral vectors. Severalkey players are dominating the global viral vector and plasmid DNA manufacturing market, contributing to a significant revenue share. The prominent players are involved in organic and inorganic strategies such asagreements, new product development launches, mergers acquisitions, joint ventures, collaborations, partnershipsand geographic expansions, to sustaintheir market positions.For instance,in April 2021, Albumedix (UK) extended itsresearch collaboration with Cobra Biologics (US) for the upstream and downstream processing of AAV and lentiviral vector. The collaboration was intended for stability enhancement and process optimization by the company. Request Free Sample: https://www.marketresearchfuture.com/sample_request/10679 Regional Analysis Based on region, North America is expected to dominate the global viral vector and plasmid DNA manufacturing market in 2020. Factors such as the presence of a largenumber of centers and institutes engaged in the RD of advanced therapies and key players in this region involved in new product launches, expansion, acquisition,and strategic collaborations are driving the market growth. For instance, In March 2021, ABECMA (idecabtagenevicleucel), a lentivirus-based gene therapy, received the US FDA approvalto treat R/R multiple myeloma. Europe is expected to hold the second-largest position in the global viral vector and plasmid DNA manufacturing market in 2021. Key factors attributing to the market growth are the increasing RD spendings to enhance research activities in the healthcare industry. For instance, according to the data published in Eurostat in 2018, the EU spent approximately 348 USD million on Research Development. The RD expenditure as a percentage of GDP was 2.18% in 2018, compared to 1.87 % in 2008. Asia-Pacific is anticipated to be the fastest-growing regional market over the assessment period due to the increasing prevalence of target disorders and healthcare needs. Furthermore, the growth of the market in the rest of the world is attributed to the rising penetration of advanced healthcare technologies in research organizations focused on viral vector and plasmid DNA manufacturing incountries such as Saudi Arabia and the UAE. Developing countries such as Argentina, Brazil, and Colombia, among others in Latin America, are also key contributors to the growth of the market. Access full report @ https://www.marketresearchfuture.com/reports/viral-vectors-and-plasmid-dna-manufacturing-market-10679 Segmentation The global viral vector and plasmid DNA manufacturing market has been segmented intovector type, workflow, disease type, application, and end user. By vector type, the market is segmented into plasmid DNA, viral vector, non-viral vector. The viral vector segment represented the dominant share in 2020, owing to the rising prevalence of target diseases and disorders, the effectiveness of viral vectors in gene therapy delivery, and rising research activities focused on viral vector-based gene cell therapies. Based on the workflow, the market is segmented into upstream processing, downstream processing. Downstream processing dominated the market for viral vectors and plasmid DNA manufacturing in 2020. Increasing adoption of downstream processing methods to help reduce contaminants originating from host cells or culture media is driving the market growth of this segment. On the basis of disease type, the market has been segmented into genetic disorders, cancer, infectious diseases, and others. Cancer held the largest market share in 2020 due to the increasing prevalence of cancer cases globally. Furthermore, geneticdisordersare expected to be the fastest-growing segment. Based on application, the market is segmented into antisense RNAi therapy, gene therapy, cell therapy, vaccinology, and research. The vaccinology segment dominated the market in 2020, owing tothe rising adoption of viral vectors in vaccine development. By end user, pharmaceutical biopharmaceutical companies and research institutes. Research institutes held a major share in the global viral vectors and plasmid DNA manufacturing market. The increasing number of research centers in gene and cell therapy coupled with rising research activities for viral vectors and plasmid DNA is projected to increase the demand for viral vectors in the global market. Key Players Some of the key players in the global Viral Vector and Plasmid DNA Manufacturing market are Cognate BioServices, Inc. (US), Catalent Pharma Solutions (US), Fujifilm Holdings Corporation (Japan), Johnson Johnson (US), Sanofi Corporation (France), F. Hoffmann-LA Roche Ltd (Switzerland), 4D Molecular Therapeutics (US), Sirion Biotech GmbH (Germany), Voyager Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Gene Therapy Catapult (UK), UniQure (Netherlands), MassBiologics (US), Renova Therapeutics (US) and Shenzhen SiBionoGeneTech Co., Ltd (China). epilepsy surgery market Size, significant challenges, Specifications, Analysis Forecast To 202711/5/2021 The epilepsy surgery market is expected to register a CAGR of 5.72% during the forecast period of 2021 to 2027.
MRFR recognizes the following companies as the key players in the global epilepsy surgery market—Stryker(US),Zimmer Biomet Holdings Inc.(US),Auris Health, Inc. (Hansen Medical, Inc.) (US), Intuitive Surgical (US),Medtronic Plc (Mazor Robotics) (Ireland), Cephalon, Inc. (US), CMR Surgical(UK), Natus Medical Incorporated(US), Livanova Plc (UK), and Monteris Medical(US). Market Highlights The global epilepsy surgery market is expected to register a CAGR of 5.72% during the forecast period and is expected to hit USD1,402.32 million by 2027. The growth of the global epilepsy surgery market is attributed to the increasing prevalence of neurological disorders leading to extensive R&D on epilepsy treatment devices and increasing cases of brain injuries due to road accidents. Furthermore, advances in robot-assisted surgery and an increase in the geriatric population are likely to drive market expansion. The collaborations of major players with regional players increase the lucrativeness of this market. Another factor propelling the growth of the epilepsy surgery market includes an increasing number of traumatic brain injuries leading to seizures and growing demand for surgical treatment of epilepsy. Furthermore, the emerging markets are anticipated to offer potential growth opportunities for global players operating in the market due to technological advancements, the growing elderly population prone to seizure disorders, and government initiatives in undertaking research studies focused on epilepsy surgery. Request Free Sample: https://www.marketresearchfuture.com/sample_request/10676 Segment Analysis The global epilepsy surgery market has been divided based on procedure type and end user. Based on procedure type, the market is segregated into resective surgery, laser interstitial thermal therapy (LITT), and others. Based on end user,the epilepsy surgery market has been divided into hospitals & clinics, specialty centers, and others. Access full report @ https://www.marketresearchfuture.com/reports/epilepsy-surgery-market-10676 Regional Analysis The global epilepsy surgery market has been studied in five regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East &Africa. The increasing prevalence of neurological disorders leading to extensive R&D on epilepsy treatment devices, increasing cases of brain injuries due to road accidents, and advances in robot-assisted surgery are the common factors driving the growth of the global epilepsy surgery market. According to the WHO, around 50 million people around the globe have epilepsy, making it one of the most common neurological diseases worldwide. It is also estimated that about70% of people living with epilepsy could live seizure-free with the help of proper diagnosis and treatment. Americas dominated the global epilepsy surgery market owing to various factors, such as the availability of well-established healthcare facilities, the high prevalence of neurological disorders, and the increasing incidence of epilepsy. North America is divided into the US and Canada.With increasing investment in R&D, the production of successful epilepsy medications, and a high prevalence of epilepsy, Europe has also evolved as a prominent market for epilepsy surgery. The Asia-Pacific region offers lucrative opportunities for players in the epilepsy surgery market, owing to the presence of a large geriatric population, governmental initiatives to improve the healthcare sector, an increase in R&D activities, and an increase in epilepsy incidence in the region.The Middle East and Africa epilepsy surgery market is segmented into major regions, namely the Middle East, Africa, and Latin America. Factors such as the increasing incidence of epilepsy, the rise in the geriatric population, and the increasing disposable income of people in the region are driving the epilepsy surgery market. Key Findings of the Study
|
|